Proteinuria following administration of immune check point inhibitor: a case-control observational study.

IF 2.2 4区医学 Q2 UROLOGY & NEPHROLOGY

BMC Nephrology Pub Date : 2024-11-27 DOI:10.1186/s12882-024-03868-5

Jianan Su, Zhuofei Bi, Pengwei Chen, Ziqing Gao, Qiongqiong Yang, Min Feng

{"title":"Proteinuria following administration of immune check point inhibitor: a case-control observational study.","authors":"Jianan Su, Zhuofei Bi, Pengwei Chen, Ziqing Gao, Qiongqiong Yang, Min Feng","doi":"10.1186/s12882-024-03868-5","DOIUrl":null,"url":null,"abstract":"Purpose: Proteinuria during treatment of immune checkpoint inhibitors (ICIs) was another renal adverse event besides from acute kidney injury. We aim to investigate the incidence and associated factors of proteinuria associated with ICIs.Method: A case-control observational study about ICIs-treated cancer patients was conducted. Clinical and laboratory data at the baseline and during the follow-up was collected. Patients developed proteinuria during ICIs-treatment were classified to the proteinuria group.Results: Between March 2019 and August 2022, 440 patients were included in the study. Forty-eight patients (10.9%) developed proteinuria after ICIs-treatment. The occurrence of acute kidney injury between the proteinuria group and the control showed no difference[1(2.1%) vs. 9(2.3%), p = 1.000]. By multivariable logistic analysis, accumulative cycle of ICIs-administration (OR 1.079, 95% CI 1.033 to 1.127, p = 0.001) and comorbidity of liver cirrhosis (OR 2.198, 95% CI 1.082 to 4.468, p = 0.030) were associated with occurrence of proteinuria after ICIs-treatment independently.Conclusions: Proteinuria could develop during the course of ICIs-therapy. Urinalysis should be monitored, especially for patients received multi-cycle of ICIs-administration and comorbid with liver cirrhosis.","PeriodicalId":9089,"journal":{"name":"BMC Nephrology","volume":"25 1","pages":"429"},"PeriodicalIF":2.2000,"publicationDate":"2024-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Nephrology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12882-024-03868-5","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: Proteinuria during treatment of immune checkpoint inhibitors (ICIs) was another renal adverse event besides from acute kidney injury. We aim to investigate the incidence and associated factors of proteinuria associated with ICIs.

Method: A case-control observational study about ICIs-treated cancer patients was conducted. Clinical and laboratory data at the baseline and during the follow-up was collected. Patients developed proteinuria during ICIs-treatment were classified to the proteinuria group.

Results: Between March 2019 and August 2022, 440 patients were included in the study. Forty-eight patients (10.9%) developed proteinuria after ICIs-treatment. The occurrence of acute kidney injury between the proteinuria group and the control showed no difference[1(2.1%) vs. 9(2.3%), p = 1.000]. By multivariable logistic analysis, accumulative cycle of ICIs-administration (OR 1.079, 95% CI 1.033 to 1.127, p = 0.001) and comorbidity of liver cirrhosis (OR 2.198, 95% CI 1.082 to 4.468, p = 0.030) were associated with occurrence of proteinuria after ICIs-treatment independently.

Conclusions: Proteinuria could develop during the course of ICIs-therapy. Urinalysis should be monitored, especially for patients received multi-cycle of ICIs-administration and comorbid with liver cirrhosis.

查看原文本刊更多论文

服用免疫检查点抑制剂后的蛋白尿：一项病例对照观察研究。

目的：免疫检查点抑制剂（ICIs）治疗期间的蛋白尿是急性肾损伤之外的另一种肾脏不良事件。我们旨在研究与 ICIs 相关的蛋白尿的发生率和相关因素：方法：我们对接受过 ICIs 治疗的癌症患者进行了一项病例对照观察研究。收集了基线和随访期间的临床和实验室数据。在接受 ICIs 治疗期间出现蛋白尿的患者被归入蛋白尿组：2019年3月至2022年8月，440名患者被纳入研究。48名患者（10.9%）在接受ICIs治疗后出现蛋白尿。蛋白尿组与对照组的急性肾损伤发生率无差异[1（2.1%） vs. 9（2.3%），P = 1.000]。通过多变量逻辑分析，使用 ICIs 的累积周期（OR 1.079，95% CI 1.033 至 1.127，P = 0.001）和肝硬化合并症（OR 2.198，95% CI 1.082 至 4.468，P = 0.030）与 ICIs 治疗后蛋白尿的发生独立相关：结论：在 ICIs 治疗过程中可能会出现蛋白尿。结论：在 ICIs 治疗过程中可能会出现蛋白尿，应监测尿液分析，尤其是接受多周期 ICIs 治疗和合并肝硬化的患者。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

BMC Nephrology UROLOGY & NEPHROLOGY-

CiteScore

4.30

自引率

0.00%

发文量

375

审稿时长

3-8 weeks

期刊介绍： BMC Nephrology is an open access journal publishing original peer-reviewed research articles in all aspects of the prevention, diagnosis and management of kidney and associated disorders, as well as related molecular genetics, pathophysiology, and epidemiology.